The Danish biopharmaceutical company Santaris Pharma has today announced that it has completed a new € 20.4 million (DKK 152 million, US$ 30 million) private investment round. Gilde Healthcare Partners, a new investor in the company, contributed € 7.5 million (DKK 56 million, US$ 11 million) of the financing, with the remaining € 12.9 million (DKK 96 million, US$ 19 million) provided by a strong international syndicate of existing investors, including BankInvest, Novo, LD, Forbion Capital Partners, Global Life Science Venture, Sunstone Capital, Seventure, Omega, Innovation Capital and members of the Santaris Pharma board and management.
